Novo Holdings to acquire majority stake in Single Use Support
Novo Holdings A/S (“Novo Holdings”) today announced that it has agreed to acquire a majority stake in Single Use Support, a fast-growing life science tools company providing advanced technology solutions for the pharmaceutical production process.
Novo Holdings will acquire an approximately 60% controlling stake, alongside the two company founders who will each retain 10% and Danaher which will retain 20% of the share capital.
Founded in 2017 in Kufstein, Austria by Johannes Kirchmair and Thomas Wurm, Single Use Support is at the forefront of transforming the production process for advanced pharmaceutical modalities with its equipment and consumables used in the bioprocessing value chain. With a focus on solutions for biological drug substances, cell and gene therapies, and mRNA vaccines, the company’s customers include leading pharma companies, biotech companies and CDMOs.
